| Generic Name |
Brand name |
Breast cancer stage |
Breast cancer subtype |
Type of therapy |
Where in the drug approval process is this treatment |
| Pembrolizumab |
Keytruda |
Stage IV (metastatic) |
Triple Negative |
Immunotherapy |
Listed on Provincial/Territorial drug Formulary |
| Pembrolizumab |
Keytruda |
Stage I, Stage II, Stage III |
Triple Negative |
Immunotherapy |
Listed on Provincial/Territorial drug Formulary |
| Pertuzumab |
Perjeta |
Stage I, Stage II, Stage III |
HER2+ |
Targeted therapy |
PCPA - Provincial & territorial price negotiation |
| Pertuzumab |
Perjeta |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Pertuzumab and Trastuzumab |
PHESGO |
Stage I, Stage II, Stage III |
HER2+ |
Targeted therapy |
CDA/INNESSS - Public funding review process |
| Pertuzumab and Trastuzumab |
PHESGO |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
PCPA - Provincial & territorial price negotiation |
| Ribociclib (plus fulvestrant) |
Kisqali |
Stage IV (metastatic) |
HR+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Ribociclib (with Aromatase Inhibitor) |
Kisqali |
Stage IV (metastatic) |
HR+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Ribociclib (with Aromatase Inhibitor) |
Kisqali |
Stage II, Stage III |
HR+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Sacituzumab govitecan |
Trodelvy |
Stage IV (metastatic) |
Triple Negative |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Sacituzumab govitecan |
Trodelvy |
Stage IV (metastatic) |
HR+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Tamoxifen |
Nolvadex-D |
Stage 0, Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+ |
Hormone therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab |
Herceptin |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Herzuma |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Ontruzant |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Kanjinti |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Ogivri |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Trazimera |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
Stage IV (metastatic) |
HER2-ultra low |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
Stage IV (metastatic) |
HER2- |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
Stage I, Stage II, Stage III |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab Subcutaneous |
Herceptin SC |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
PCPA - Provincial & territorial price negotiation |
| Tucatinib |
Tukysa |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Vinorelbine |
Navelbine, and various generic versions |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |